VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

WCN 2021 | Neuroregenerative agents in progressive multiple sclerosis

Xavier Montalban, MD, PhD, MBA, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the clinically unmet needs in progressive multiple sclerosis (MS). Anti-inflammatory drugs such as siponimod and ocrelizumab are common therapies for progressive MS. However, there is currently a lack of neuroregenerative treatments for progressive MS that can halt or even reverse disease progression. This constitutes a critical clinical need in progressive MS. Research aiming to identify compounds with clear neuroregenerative properties is currently underway and may improve the treatment of progressive MS in the future. This interview took place during the XXV World Congress of Neurology (WCN).


Dr Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.